Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Oct
16
Today In Oncology
Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Amyloidosis: Novel Treatments Could Improve Poor Outcomes
Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo